Novolog Mix 70/30 Flexpen is a drug owned by Novo Nordisk Inc. It is protected by 13 US drug patents filed from 2013 to 2019. Out of these, 1 drug patents are active and 12 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 23, 2032. Details of Novolog Mix 70/30 Flexpen's patents and their expiration are given in the table below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
US9265893 | Injection button |
Sep, 2032
(7 years from now) | Active |
US7762994 | Needle mounting system and a method for mounting a needle assembly |
May, 2024
(6 months ago) |
Expired
|
US8579869 | Needle mounting system and a method for mounting a needle assembly |
Jun, 2023
(1 year, 5 months ago) |
Expired
|
USRE41956 | Dose setting limiter |
Jan, 2021
(3 years ago) |
Expired
|
USRE43834 | Injection syringe |
Jan, 2019
(5 years ago) |
Expired
|
US6004297 | Injection syringe |
Jan, 2019
(5 years ago) |
Expired
|
US5866538 (Pediatric) | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) |
Expired
|
US5866538 | Insulin preparations containing NaCl |
Jun, 2017
(7 years ago) |
Expired
|
US5618913 (Pediatric) | Insulin analogues |
Dec, 2014
(9 years ago) |
Expired
|
US5618913 | Insulin analogues |
Jun, 2014
(10 years ago) |
Expired
|
US5840680 | ASPB28 insulin crystals |
Sep, 2013
(11 years ago) |
Expired
|
US5547930 | AspB28 insulin crystals |
Sep, 2013
(11 years ago) |
Expired
|
US5834422 | AspB28 insulin compositions |
Sep, 2013
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Novolog Mix 70/30 Flexpen's patents.
Latest Legal Activities on Novolog Mix 70/30 Flexpen's Patents
Given below is the list of recent legal activities going on the following patents of Novolog Mix 70/30 Flexpen.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 12th Year, Large Entity | 16 Dec, 2021 | US7762994 |
Payment of Maintenance Fee, 8th Year, Large Entity | 22 Apr, 2021 | US8579869 |
Payment of Maintenance Fee, 8th Year, Large Entity | 22 Dec, 2017 | US7762994 |
Patent Issue Date Used in PTA Calculation Critical | 12 Nov, 2013 | US8579869 |
Recordation of Patent Grant Mailed Critical | 12 Nov, 2013 | US8579869 |
Email Notification Critical | 24 Oct, 2013 | US8579869 |
Issue Notification Mailed Critical | 23 Oct, 2013 | US8579869 |
Dispatch to FDC | 14 Oct, 2013 | US8579869 |
Application Is Considered Ready for Issue Critical | 08 Oct, 2013 | US8579869 |
Printer Rush- No mailing | 05 Oct, 2013 | US8579869 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Novolog Mix 70/30 Flexpen and ongoing litigations to help you estimate the early arrival of Novolog Mix 70/30 Flexpen generic.
Novolog Mix 70/30 Flexpen's Litigations
Novolog Mix 70/30 Flexpen been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jan 23, 2014, against patent number US9265893. The petitioner , challenged the validity of this patent, with Torben Stroem Hansen et al as the respondent. Click below to track the latest information on how companies are challenging Novolog Mix 70/30 Flexpen's patents.
Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
---|---|---|---|---|
US9265893 | January, 2014 |
Decision
(08 Sep, 2015) | Torben Stroem Hansen et al |
Several oppositions have been filed on Novolog Mix 70/30 Flexpen's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Novolog Mix 70/30 Flexpen's generic, the next section provides detailed information on ongoing and past EP oppositions related to Novolog Mix 70/30 Flexpen patents.
Novolog Mix 70/30 Flexpen's Oppositions Filed in EPO
Novolog Mix 70/30 Flexpen has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 18, 2010, by Sanofi-Aventis Deutschland Gmbh. This opposition was filed on patent number EP06121820A. Click below to reveal the latest opposition data.
Application | Filing Date | Opposition Party | Legal Status |
---|---|---|---|
EP08708028A | Jul, 2011 | Bock Wolfgang | Patent maintained as amended |
EP06121820A | May, 2010 | SANOFI-AVENTIS DEUTSCHLAND GMBH | Opposition rejected |
US patents provide insights into the exclusivity only within the United States, but Novolog Mix 70/30 Flexpen is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Novolog Mix 70/30 Flexpen's family patents as well as insights into ongoing legal events on those patents.
Novolog Mix 70/30 Flexpen's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Novolog Mix 70/30 Flexpen's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 23, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Novolog Mix 70/30 Flexpen Generics:
There are no approved generic versions for Novolog Mix 70/30 Flexpen as of now.
Alternative Brands for Novolog Mix 70/30 Flexpen
Novolog Mix 70/30 Flexpen which is used for managing diabetes mellitus., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Drug Owner | Drug Name | Treatment Area | ||||||
---|---|---|---|---|---|---|---|---|
Novo Nordisk Inc |
| |||||||
Sanofi Aventis Us |
|
About Novolog Mix 70/30 Flexpen
Novolog Mix 70/30 Flexpen is a drug owned by Novo Nordisk Inc. It is used for managing diabetes mellitus. Novolog Mix 70/30 Flexpen uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as an active ingredient. Novolog Mix 70/30 Flexpen was launched by Novo Nordisk Inc in 2001.
Approval Date:
Novolog Mix 70/30 Flexpen was approved by FDA for market use on 01 November, 2001.
Active Ingredient:
Novolog Mix 70/30 Flexpen uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant ingredient
Treatment:
Novolog Mix 70/30 Flexpen is used for managing diabetes mellitus.
Dosage:
Novolog Mix 70/30 Flexpen is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
Strength | Dosage Form | Availability | Application Pathway |
---|---|---|---|
210 UNITS/3ML; 90 UNITS/3ML (70 UNITS/ML; 30 UNITS/ML) | INJECTABLE | Prescription | SUBCUTANEOUS |